Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.53 |
| ▸ | MEN1 | O00255 | 5/20 | 0.53 |
| ▸ | TP53 | P04637 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | CASP3 | P42574 | 2/20 | 0.48 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.48 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 2/20 | 0.48 |
| ▸ | CA1 | P00915 | 2/20 | 0.48 |
| ▸ | CA2 | P00918 | 2/20 | 0.48 |
| ▸ | CA9 | Q16790 | 2/20 | 0.48 |
| ▸ | IDO1 | P14902 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3301616 | 1.00 | MAPT (0.53) | MAPTKMT2AMEN1TP53GAA | |
| SCHEMBL14113477 | 1.00 | MAPT (0.53) | MAPTKMT2AMEN1TP53GAA | |
| SCHEMBL3302220 | 0.93 | MAPT (0.54) | MAPTKMT2AMEN1TP53GAA | |
| SCHEMBL3302218 | 0.93 | MAPT (0.54) | MAPTKMT2AMEN1TP53GAA | |
| SCHEMBL13389690 | 0.90 | MAPT (0.51) | MAPTKMT2AMEN1TP53GAA | |
| SCHEMBL3301426 | 0.88 | ACKR3 (0.41) | MAPTKMT2AMEN1TP53GAA | |
| SCHEMBL3301423 | 0.88 | ACKR3 (0.41) | MAPTKMT2AMEN1TP53GAA | |
| SCHEMBL3303299 | 0.88 | MAPT (0.51) | MAPTKMT2AMEN1TP53GAA | |
| SCHEMBL3303302 | 0.88 | MAPT (0.51) | MAPTKMT2AMEN1TP53GAA | |
| SCHEMBL3301627 | 0.86 | MAPT (0.54) | MAPTKMT2AMEN1TP53GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100093733-A1 | AMIDE AND UREA DERIVATIVES FOR THE TREATMENT OF METABOLIC DISEASES | PROSIDION LIMITED (GB) | 2010-04-15 | — | — | US | disclosed |
| US-20100093733-A1 | AMIDE AND UREA DERIVATIVES FOR THE TREATMENT OF METABOLIC DISEASES | PROSIDION LIMITED (GB) | 2010-04-15 | — | — | US | disclosed |
| US-20100093733-A1 | AMIDE AND UREA DERIVATIVES FOR THE TREATMENT OF METABOLIC DISEASES | PROSIDION LIMITED (GB) | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093733-A1 | AMIDE AND UREA DERIVATIVES FOR THE TREATMENT OF METABOLIC DISEASES | CPS1, GOT2, GPR119 | MAPT 1308/4885KMT2A 1665/4885MEN1 2505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.